Dr Enrica Alteri has extensive experience in drug discovery and clinical safety and worked at the European Medicines Agency for 8 years, serving on its Executive Board Prof Jeffrey Skopek is Associate ...

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...

The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

Research collaboration leverages bit.bio's machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.